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Abstract
The FOXL2 forkhead transcription factor is expressed in ovarian granulosa cells, and mutated FOXL2 causes the
blepharophimosis, ptosis and epicanthus inversus syndrome (BPES) and predisposes to premature ovarian failure.
Inactivation of Foxl2 in mice demonstrated its indispensability for female gonadal sex determination and ovary
development and revealed its antagonism of Sox9, the effector of male testis development. To help to define the regulatory
activities of FOXL2, we looked for interacting proteins. Based on yeast two-hybrid screening, we found that FOXL2 interacts
with PIAS1 and UBC9, both parts of the sumoylation machinery. We showed that human FOXL2 is sumoylated in transfected
cell lines, and that endogenous mouse Foxl2 is comparably sumoylated. This modification changes its cellular localization,
stability and transcriptional activity. It is intriguing that similar sumoylation and regulatory consequences have also been
reported for SOX9, the male counterpart of FOXL2 in somatic gonadal tissues.
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Introduction
Mutations in FOXL2 cause the blepharophimosis, ptosis and
epicanthus inversus syndrome (BPES MIM 110100) either with
(Type I) or without (Type II) premature ovarian failure [1]. We
created a mouse model for BPES through the disruption of Foxl2,
and showed that Foxl2 is required for ovarian follicle formation
[2]. The failure of Foxl2-negative granulosa cells to sustain
follicle formation is a primary cause of ovarian failure, leading to
subsequent deregulated oogenesis by an unknown mechanism
[2]. In addition to its role in follicle formation and oocyte growth
dynamics, we demonstrated an apparent role for FOXL2 in
repressing male sex determination. A male differentiation
program is initiated in Foxl2
2/2 female ovaries, with Sox9,t h e
master effector of gonadal testis differentiation, sharply upregu-
lated between birth and 1 week postnatum [3]. During this
transition, Foxl2-null ovaries contain cords, delimited by basal
lamina, that enclose cells with male Sertoli-like features. Basedon
these observations and supporting correlated global gene
expression changes, we have suggested that mammalian female
sex determination is labile and may require Foxl2 activity in the
gonadal soma throughout ovary development and maturation
[3]. The data are consistent with sex determination occurring in
the bipotential gonad with a direct parallelism between two
intrinsically antagonistic transcription factors, Foxl2 and Sox9,
o n ew i t hak e yr o l ei nf e m a l ea n dt h eo t h e ri nm a l em a m m a l i a n
gonadal development [4]. In fact, SOX9 heterozygous mutations
cause the severe campomelic dysplasia syndrome (CMPD MIM
114290), in which - in addition to defects in cartilage and bone -
about 75% of affected XY individuals have a sex-reversed
phenotype [5].
Here we provide evidence that the antagonists Foxl2 and Sox9
also show a parallel modulation of their activity by sumoylation. As
described for SOX9 [6,7], we found that FOXL2 interacts with
PIAS1 and is sumoylated. Sumoylation is a highly dynamic and
reversible process, exerting pleiotropic biological effects that
include changes in subcellular localization, protein partnering
and modulation of the DNA binding and activity of transcription
factors, which are the largest group of target proteins affected by
sumoylation [8,9]. In the case of FOXL2, we report changes in its
localization, stability and activity.
Methods
Ethics Statement
Mice were manipulated and housed according to the European
Community Council Directive (EEC/609/86) and to the Italian
guidelines DL 116/1992. The experimental protocol and the
detailed application form that focuses on how the animals have
been used, has been approved by Italy’s National Institute of
Health, in particular by the Service for Biotechnology and Animal
Welfare, and by University of Cagliari.
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C57BL/6 female mice were obtained from Charles River
laboratory (Calco - Lecco, Italy). Mice were housed conventionally
in a constant temperature (20–24uC) and humidity (50–60%)
animal room and with a 12 h light–dark cycle. All mice had free
access to food and water. Mice were sacrificed at 4 weeks of age by
CO2 asphyxiation or cervical dislocation.
Yeast Two Hybrid Assay
A yeast two-hybrid screen was performed using the Matchma-
ker
TM Two-Hybrid System 3 (Clontech). Full-length FOXL2
cDNA was cloned into pGBKT7 vector, and transformed into
AH109 yeast cells. Human Ovary MATCHMAKER cDNA
Library (Clontech) cloned in the pACT2 vector was transformed
into AH109 cells already containing FOXL2 as a bait, and co-
transformants were screened on selection plates according to the
Clontech protocol. False positives were reduced by performing an
X-alpha-galactosidase assay.
Cell Culture, DNA Transfections, Cell Lysis
COS-7 cells (ATCC) were grown in DMEM (Dulbecco’s
Modified Eagle’s Medium) supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM
glutamine. COS-7 cells were transfected using Lipofectamine 2000
(Invitrogen) and after 48 h were lysed with modified RIPA buffer
(140 mM NaCl, 10 mM TrisHCl pH 7.5, 1 mM EDTA, 1%
Triton x-100, 0.1% Sodium deoxycholate) containing Complete
Protease Inhibitor Cocktail (Roche) and 40 mM of N-ethylmalei-
mide (NEM), according to Hattori et al. 2006 (6). After brief
sonication and 30 min on ice, the lysates were centrifuged at 4uC,
160006g, for 20 min. Protein concentrations were measured by
Bio-Rad Protein Assay. For half-life determination and stability
assays, Cycloheximide (Sigma-Aldrich, C7698) at final concentra-
tion 100 mg/ml, and MG132 (Calbiochem) at final concentration
10
28 M were used for the indicated times. Alpha T31 pituitary
mouse cell line (a-T31) were kindly donated by P.L. Mellon
(Department of Reproductive Medicine, University of California,
San Diego, USA) and were grown in RPMI 1640 supplemented
with 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml
streptomycin and 2 mM glutamine.
Constructs, Immunoblotting and Immunoprecipitation
Human full length PIAS1 and UBC9 cDNA obtained from
pACT2 vectors isolated by two hybrid screen, and FOXL2 were
cloned into the pCRUZ-HA or pCRUZ-myc vectors (Santa Cruz).
Full length SUMO-1 cDNA was derived from a pGEX2T-SUMO-
1 vector kindly provided by Ronald T. Hay (Wellcome Biocentre,
University of Dundee, U.K.), and cloned into the pCRUZ-HA
expression vector. For immunoprecipitation, the lysates were
diluted 4-fold in co-immunoprecipitation buffer (2 mM Hepes
pH 7.9, 20 mM NaCl, 0,01% Tween 20, 1 mM DTT, 10%
glycerol) and incubated overnight with 25 ml of anti-myc (Santa
Cruz) or anti-FOXL2 agarose-conjugate antibody at 4uC. The
immunocomplexes were washed 5 times with 800 ml of co-
immunoprecipitation buffer, and immunoprecipitated proteins
were released from the antibody-agarose-conjugate by the addition
of 25 ml of glycine pH 2.5 with a 2 min incubation in ice. Samples
were fractionated on a 7.5% SDS-polyacrylamide gel, then
transferred to PVDF membranes (HYBOND-P, Amersham
Biosciences), hybridized with the primary antibody overnight,
then with a horseradish peroxidase-conjugated secondary antibody
that was detected by enhanced chemiluminescence (ECL,
Amersham Biosciences). The primary antibodies used were mouse
anti-myc (Santa Cruz sc40, 1:200), rabbit anti-HA (Santa Cruz
sc805, 1:200), rabbit anti-SUMO-1 (Santa Cruz sc9060, 1:500),
rabbit anti-UBC9 (Santa Cruz sc10759, 1:400) rabbit anti-PIAS1
(Santa Cruz sc14016 1:500) rabbit anti-ubiquitin (Sigma-Aldrich
U5379, 1:500) and rabbit polyclonal anti-FOXL2 raised against
residues DHDSKTGALHSRLDL (Eurogentec s.a., Belgium) and
used after affinity purification. Secondary antibodies were
purchased by Santa Cruz biotechnology inc, goat anti-mouse
IgG (Santa Cruz sc2005, 1:100,000), goat anti-rabbit IgG (Santa
Cruz sc2004, 1:100,000). Densitometric analysis to evaluate the
intensities of protein bands was performed by Image J software
(http://rsbweb.nih.gov/ij/).
Site-Directed Mutagenesis
FOXL2 mutants FOXL2-K25R, FOXL2-K87R, FOXL2-
K114R and FOXL2-K150R, single or all 4 together (FOXL2-
KFULL), were generated in the pCRUZ-myc FOXL2 vector
using the QuickChange Site-Directed Mutagenesis kit (Stratagene)
according to the manufacturer’s protocol. Primer sequences are
available on request.
Immunofluorescence and Confocal Microscopy
4 week ovaries isolated from C57BL/6 mice were fixed in
Histochoice (Amresco, Solon, OH, USA) at room temperature for
4 h. Sections were treated with 3% H2O2 for 1 h and unmasked
with Citrate Buffer solution (LAB VISION corp. AP-9003-500)
and with 0.01 M EDTA, pH 8. Slides were blocked with
DakoCytomation Protein Block Serum-free (X0909) for 30 min
at room temperature and incubated overnight at 4uC with primary
antibodies. Primary antibody dilutions were as follows: anti-
FOXL2 goat polyclonal (ABCAM ab5096, 1:200), anti-SUMO-1
rabbit polyclonal (Santa Cruz sc9060, 1:25), anti-UBC9 rabbit
(Santa Cruz sc10759, 1:100). COS-7 cells were co-transfected
either with pCRUZ-myc FOXL2 wild type or mutated forms and
pCRUZ-HA SUMO-1 for 48 h. Cells fixed at room temperature
for 1 h in Histochoice were unmasked in Citrate Buffer solution
for 20 sec in a microwave, permeabilized with 20 mM Tris-HCl,
pH 7.6, 137 mM NaCl, and 0.1% Tween 20 containing 5% skim
milk for 30 min at room temperature (according to Hattori et al.,
ref. 6) and incubated with primary antibodies overnight at 4uC.
Alexa Fluor 594 anti-goat, Alexa Fluor 633 anti-mouse, and Alexa
Fluor 488 anti-rabbit secondary antibodies (Molecular Probes)
were diluted 1:500. Immunofluorescence analysis was performed
using a Leica DMIRE2-TCS-SL Confocal Laser Scanning
microscope (488 to 633 excitation wavelength); images were
acquired with a 40X objective.
Transactivation Assays
A 972 bp fragment of the human StAR promoter was amplified
by PCR from genomic DNA using the following primers: forward
59 ctctcgcgagagggtggtt 39 and reverse 59 gcttgaatgtcgctagcagc 39.
This PCR product was digested with NruI and HindIII and cloned
into the plasmid vector pGL3 basic (Promega). COS-7 cells were
transfected using Lipofectamine 2000 (Invitrogen) with 1 mgo f
human pCRUZ-myc FOXL2, 1 mg of human StAR promoter
luciferase construct, and 4 mg of human pCRUZ-HA SUMO-1. A
Renilla luciferase control vector (Promega) was co-transfected to
normalize data. After 48 h transfected cells were treated according
to Dual-Luciferase Reporter Assay System (Promega) protocol and
luciferase activities was measured. At least 3 independent
transfections were carried out and each experiment was performed
in quadruplicate. Values are mean +/2 SD of at least 4
independent assays. Statistical significance was estimated by
Student’s t-Test.
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Although the importance of the forkhead transcription factor
FOXL2 in ovarian development and function is established,
regulation of its action is not well understood. We found that post-
translational modification by sumoylation affects both FOXL2
metabolism and activity.
Forkhead Transcription Factor FOXL2 Interacts with
PIAS1 and UBC9, Members of the Sumoylation Machinery
To look for proteins interacting with FOXL2, we initially
performed a yeast two hybrid assay to screen a human ovary
cDNA library. Both bait plasmid PGBKT7, containing the full-
length FOXL2 fused in-frame to the DNA binding domain of
Gal4, and a human ovary cDNA library, fused to the Gal4
activator domain in PGADT7, were introduced into AH109 yeast
cells. A total of 4610
6 independent transformants were screened
for the expression of four reporter genes (ADE2, HIS3, MEL, and
lacZ). Among 288 colonies that tested positive, DNA sequencing
identified 8 PIAS1 clones and 69 UBC9 clones. In controls, co-
transformation of empty prey plasmid with a FOXL2, PIAS1, or
UBC9 bait plasmid failed to activate expression of reporter genes.
PIAS1 and UBC9 are both tell-tale members of the sumoylation
machinery. In outline, sumoylation involves the reversible covalent
attachment of a SUMO protein moiety (about 11 kDa) to lysine
residues in proteins through a three-step process, engaging the E1-
activating molecules SAE1/SAE2, the E2-conjugating enzyme
UBC9, and E3 ligases such as PIAS in mammalian cells that
confer specificity [8,9].
The FOXL2 association with PIAS1 and UBC9 was validated
by several approaches: 1. Co-transformation in yeast. AH109 yeast
strain was co-transformed with the pGBKT7 vector expressing
full-length FOXL2 and the pGADT7 vector expressing full-length
PIAS1 or UBC9. The empty pGADT7 vector was also re-
transformed along with FOXL2 as a control. FOXL2 bound
strongly to PIAS1 and also bound, though more weakly, to UBC9;
the same interactions were detected when the PIAS1 and UBC9
were switched from the pGADT7 vector to pGBKT7 and FOXL2
from the pGBKT7 to the pGADT7 vector and were re-tested in
the two-hybrid assay. The strength of the interactions was
determined by quantitative measurement in liquid b-galactosidase
assays (data not shown). 2. Co-immunoprecipitation in vivo. More
direct evidence of interaction was obtained when COS-7 cells
were co-transfected with myc-FOXL2 and HA-UBC9 or with
myc-PIAS1 and HA-FOXL2 constructs. A protein lysate from the
cells was then immunoprecipitated using an anti-myc antibody
and analysed by Western blotting with anti-tag and anti-UBC9 or
anti-PIAS1 specific antibodies. Binding to FOXL2 was confirmed
for both PIAS1 and UBC9 (Fig. 1A, B).
FOXL2 is Sumoylated and Co-Localizes with SUMO-1
To test whether FOXL2 undergoes sumoylation, we transiently
co-transfected monkey kidney COS-7 cell lines with constructs
encoding myc-FOXL2 wild type and HA-SUMO-1. Cell lysates
were prepared and FOXL2 was immunoprecipitated by anti-myc
antibody, then analysed by Western blotting. Anti-FOXL2
antibody detected additional higher molecular weight species of
about 105–160 kDa (versus 50 kDa for the native protein) in the
presence of SUMO-1. They were missing or reduced in the sample
transfected with FOXL2 alone (Fig. 1C). The observations in
transfected COS-7 cells were corroborated for the endogenous
Foxl2 mouse homolog by immunoprecipitation in a-T31 pituitary
cells (Fig. 1D). These higher band(s) were also detected by anti-
SUMO-1 antibody (Fig. 1C, D). The 105–160-kDa ‘‘poly SUMO-
FOXL2’’ species appear as single or double bands in different
experiments, and this could be assessed by antibodies/experimen-
tal condition/tag used. Furthermore, 4 week-old mouse ovaries
were lysed with and without NEM, which inhibits desumoylases,
and the protein extracts were immunoblotted with anti-FOXL2
antibody. Only in the NEM-treated extracts were the higher
molecular weight band(s) evident (Fig. 1E). When FOXL2 was co-
transfected with SUMO-1 in COS-7 cells, co-localization was
observed by confocal microscopy in structures reminiscent of PML
(promyelocytic leukaemia) bodies (Fig. 1F). SUMO proteins have
been shown to localize to specific subnuclear structures known as
PML-containing nuclear bodies, associated with the nuclear
matrix [10,11]. These findings are consistent with sumoylation
of FOXL2 in vivo. Addition of a single SUMO-1 moiety would add
a molecular mass of about 11 kDa, so that the apparent increase of
more than 50 kDa in denaturing gels suggests that 3 to 5 SUMO
groups might be conjugated on FOXL2 to account for the various
species seen and there might be multiple sumoylation sites with a
single SUMO-1 moiety.
PIAS1 Co-Localizes with FOXL2 and Acts as an E3 Ligase
for FOXL2 Sumoylation
Sumoylation proceeds via a multi-enzyme pathway. SUMO-1 is
activated by an E1 activating enzyme (the heterodimer Aos1/
Uba2) and is then transferred to the E2 conjugating enzyme
(UBC9), and thence to a specific lysine in the target protein by an
a E3 ligase. Proteins of the PIAS family can act as SUMO-3
ligases, significantly enhancing the level of the substrate sumoyla-
tion [8]. To determine whether PIAS1 can increase FOXL2
sumoylation, we co-transfected COS-7 cells with myc-FOXL2 and
HA-PIAS1, both in the presence or absence of NEM. We found
that FOXL2 and PIAS1 co-localize in the nucleus (Fig. 1G); that
PIAS1 caused notable enhancement of the 105–160-kDa ‘‘poly
SUMO-FOXL2’’ species; and that NEM increased the intensity of
these bands (Fig. 1H).
Does Sumoylation Regulate FOXL2 Stability?
Western blot analysis indicated that co-transfection of FOXL2
and PIAS1, or UBC9, or SUMO-1 significantly increased the
protein levels of FOXL2 and of sumoylated FOXL2, as revealed
by quantification of the FOXL2-SUMO-1 band by densitometric
analysis (Fig. 2A). The interaction of FOXL2 with PIAS1, UBC9
and/or SUMO-1 might thus lead to stabilization of the 50 KDa
FOXL2 polypeptide in a dose-sensitive manner (Fig. 2A, B). These
bands were not detected or strongly reduced when the sample was
not treated with NEM (Fig. 2A).
According to Protparam software (http://www.expasy.ch/tools/
protparam.html) the estimated half-life for FOXL2 in mammalian
reticulocytes is around 30 hours, and the instability index is
computed to be 66.04, classifying the protein as unstable. We
confirmed the prediction of FOXL2 half-life by the addition of
cycloheximide, an inhibitor of protein biosynthesis in eukaryotic
organisms, in a time-course experiment, followed by immunoblot-
ting with anti-myc antibody (Fig. 2C). The treatment with both
cycloheximide and MG132, a proteasome inhibitor, showed that
the stability of FOXL2 is dependent on the co-transfection with
SUMO-1. Furthermore it is clear that FOXL2 stability is not
dependent on MG132 treatment, suggesting that FOXL2 degra-
dation is not mediated by proteasomes. To check if FOXL2 is post-
translationally modified by ubiquitin, which targets proteins to be
degradated by proteasome, we performed a Foxl2 immunoprecip-
itation in a-T31 cell lines, followed by western blot with anti-
ubiquitin antibody. This assay shows that Foxl2 is not conjugated
with ubiquitin (data not shown). This is consistent with reports
SUMO-1 Modification of FOXL2
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with PIAS1 and UBC9: COS-7 cells were co-transfected with pCRUZ-HA-FOXL2 and pCRUZ-myc-PIAS1 (A), or with pCRUZ-myc-FOXL2 and pCRUZ-HA-
UBC9 (B) or with HA and myc empty vectors (2). Lysates were immunoprecipitated with anti-myc agarose conjugated antibody and analysed by
western blotting with anti-FOXL2, anti-PIAS1 and anti-UBC9 antibodies. Mock IP consisted in an immunoprecipitation with only protein-A beads,
without antibody. Expression of all proteins was also analysed in total lysates (input). C. FOXL2 is sumoylated in transfected COS-7 cells: COS-7 cells
were transfected with pCRUZ-myc-FOXL2 (0.5 mg) alone or with pCRUZ-HA-SUMO-1 (4.5 mg), or with HA and myc empty vectors (2). Lysates were
immunoprecipitated with anti-myc agarose conjugated antibody, and analysed by western blotting using anti-FOXL2 antibody (upper panel) or anti-
SUMO-1 antibody (lower panel). Both antibodies recognized band(s) of about 105-160-kDa indicated by brackets ([), not present in the transfection of
FOXL2 alone. D.,E. FOXL2 is sumoylated in vivo in physiological conditions: (D) Immunoprecipitation was done using anti-FOXL2 antibody on a-T31
cell lysate and the eluate analyzed by western blotting using anti-FOXL2 antibody (left panel) or anti-SUMO-1 antibody (right panel). Both antibodies
recognized band(s) of about 105–160-kDa indicated by brackets ([). The asterisk indicates the FOXL2 signal from the previous hybridization. (E) 4-
week old mouse ovaries were lysed with or without NEM, 60 mg of protein was loaded on SDS PAGE, electrophoresed, and then immunoblotted.
Western blotting with an anti-Foxl2 antibody showed a 45 kDa band corresponding to native Foxl2 and a slower migrating band of about 105–
160 kDa, also recognised by anti-Sumo-1 antibody (not shown). F. FOXL2 and SUMO-1 co-localize in the nucleus: pCRUZ-myc-FOXL2 and pCRUZ-HA-
SUMO-1 were co-transfected into COS7 cells, and immunofluorescence was performed using anti-myc and anti-HA antibody. In red (Alexa 633) is
shown FOXL2, in green (Alexa 488) SUMO-1. The yellow colour indicates co-localization, and is particularly seen in spots resembling PML bodies. G.
Wild type FOXL2 co-localizes with PIAS1 in the nucleus: COS-7 cells were co-transfected with pCRUZ-myc-FOXL2 and pCRUZ-HA-PIAS1. The
intracellular distribution of FOXL2 (red) and PIAS1 (green) was detected by indirect immunofluorescence with mouse anti-myc and rabbit anti-HA
primary antibodies and Alexa Fluor 633 anti-mouse and Alexa Fluor 488 anti-rabbit secondary antibodies. H. PIAS1 enhances FOXL2 sumoylation:
COS-7 cells were co-transfected with pCRUZ-myc-FOXL2 and pCRUZ-HA-PIAS1. And lysed with or without NEM. Lysates were immunoblotted with
anti-FOXL2 antibody and densitometric analysis was performed on sumoylated band using Image J software. Densitometric analysis is reported
compared to that in lane 1.
doi:10.1371/journal.pone.0009477.g001
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for proteins with a half-life of 3–5 hours, while for proteins with
half-lives longer than 30 hours degradation is linked to lysosomes
[12]. These results suggest a role of sumoylation in regulating
FOXL2 stability. It seems likely, from other cases that have been
studied in detail, that sumoylation can directly affect protein
stability, but a direct effect has not been proven in this case.
Foxl2, Pias1, Ubc9 and Sumo-1 Are Co-Localized in the
Mouse Ovary
Recently Shao et al [13,14] reported that Sumo-1, based on
immunohistochemical analyses, is expressed in both healthy and
atretic mouse granulosa cells in vivo, suggesting that Sumo-1 may
function both during follicular development and atresia. We
performed western blotting on protein extracts and immunofluo-
rescence on sections of 4-week mouse ovaries, using specific
antibodies for Foxl2, Pias1, Ubc9 and Sumo-1. The signal for
Pias1 by immunofluorescence was low and visible only in western
blotting. The other proteins were detected both by western blotting
(Fig. 3A) and immunofluorescence (Fig. 3B). Foxl2, expressed in the
granulosa cells of ovarian follicles at different stages of development,
was co-localized with both Sumo-1 and Ubc9 (Fig. 3B).
Identification of Sumoylation Sites
More than two-thirds of the known SUMO substrate proteins
have a consensus sumoylation motif YkxE, where Y represents a
hydrophobic amino acid, X represents any amino acid and K is
the leucine residue where SUMO-1 is covalently conjugated [8].
We used a computational method ‘‘The SUMOplot
TM Analysis
Program (http://www.abgent.com/sumoplot.html)’’ to predict
and score potential sumoylation sites within the FOXL2 protein
(Fig. 4A). The program identified 7 putative sumoylation sites at
positions K25, K36, K48, K54, K87, K114, and K150, all of
which lie in and around the forkhead domain. The sites containing
lysine residues 54, 87, 114 and 150 are strongly conserved across
many phyla, whereas those containing the lysine residues 25, 36
and 48 are found only in mammals. The alignment of FOXL2
amino acid sequences retrieved from the Ensembl database
(http://www.ensembl.org), was done by the ClustalW2 Web
based tool (http://www.clustal.org) (Fig. 4B).
We created FOXL2 mutants in which the lysines of the higher
score putative sumoylation sytes (K25, K87, K114, K150) were
changed to arginine by site-directed mutagenesis, alone or all
together (KFULL). After transfection in COS-7 cells of mutant
forms of myc-FOXL2 with and without SUMO-1, lysates were
Figure 2. FOXL2 stability is increased by SUMO-1 and is not dependent on proteasome-mediated degradation. A. Sumoylation
regulates FOXL2 stability: COS-7 cells were co-transfected with pCRUZ-myc-FOXL2 (0.5 mg) and increasing amounts of pCRUZ-HA-UBC9 or pCRUZ-
HA-PIAS1(3.5–4.5 mg) or pCRUZ-HA-SUMO-1 (4.5 mg). Lysates treated with and without NEM were analysed by immunoblotting with anti-FOXL2
antibody. The bracket shows slower migrating bands of about 105–160 kDa. Densitometric analysis was performed on sumoylated band using Image
J software and is reported compared to that in lane 1. B. FOXL2 stabilization is mediated by SUMO-1 in a dose-dependent manner: COS7 were
transfected with 500 ng of pCRUZ-myc-FOXL2 and increasing amounts of pCRUZ-HA-SUMO-1 (0, 1, 2, 3, 4 mg). Immunoblotting against myc shows
that FOXL2 increases with the augmentation of SUMO-1. In the lower panel anti-actin is used as loading control. C. FOXL2 stability is not dependent
on ubiquitination and proteasome-mediated degradation: COS7 cells were transfected with pCRUZ-HA-FOXL2 alone and with pCRUZ-HA-SUMO-1 in
quadruplicate. After 12 h of transfection, cells were lysed (t0) or treated with cycloheximide (inhibitor of protein biosynthesis), cycloheximide and
MG132 (proteasome-inhibitor) or neither. After 36 h cells were lysed and 50 ug of protein were blotted and hybridization performed with anti-myc
antibody.
doi:10.1371/journal.pone.0009477.g002
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putative sumoylated band(s) appear in K25 and K87 mutants, but
are strongly reduced/abrogated in K114, K150, and FOXL2-
KFULL (Fig. 5A).
Sumoylation Affects FOXL2 Localization in COS-7 Cells
To assess any effect of SUMO modification on the subnuclear
localization of FOXL2, we transiently co-transfected COS-7 cells
with myc-FOXL2 wild type (WT) or mutated forms and HA-
SUMO-1 and then examined localization in confocal microscopy
by immunofluorescence. Anti-myc antibody showed nuclear
localization of FOXL2 WT; anti-HA antibody revealed that both
FOXL2 and SUMO-1 at least partially co-localized in the nucleus
(Fig. 1F). FOXL2-K25R or FOXL2-K87R did not change the
nuclear co-localization (Fig. 5B). By contrast, when K114 or K150
were individually mutated – or when all 4 possible sumoylation sites
weremutated (FOXL2-KFULL),a considerable fractionofFOXL2
became cytoplasmic, in addition to some in the nucleus (Fig. 5B).
Sumoylation Regulates FOXL2 Transcriptional Activity
Thus far, the best characterized FOXL2 target genes are
involved in steroidogenesis: the gonadotropin-releasing hormone
receptor (GnRHr), the alpha subunit of the gonadotropins (Cga),
and the steroidogenic acute regulatory protein (StAR) [15–17]. In
Figure 3. Foxl2, Sumo-1 and Ubc9 are expressed in mouse ovary. A. Pias1, Ubc9 and Sumo-1 are expressed in 4 week mouse ovaries: 4-week
old mouse ovaries were lysed and analysed by immunoblotting with anti- Pias1, Ubc9, and Sumo-1 specific antibodies. 50 ug of protein were loaded
in each lane. B. Co-Localization of Foxl2, Sumo-1 and Ubc9 in 4 week-old mouse ovary: Hybridization with anti-Foxl2 (red) and anti-Ubc9 (green) or
anti-Sumo-1 (green) antibodies. Yellow spots in the 406 magnification show the co-localization of Foxl2 with Ubc9 and Sumo-1, especially in
primordial and primary follicle granulosa cells. Immunofluorescence analysis was performed using a Leica DMIRE2-TCS-SL Confocal Laser Scanning
microscope (from 488 to 633 excitation wavelength).
doi:10.1371/journal.pone.0009477.g003
Figure 4. Sumoylation sites prediction. A. The SUMOplot
TM Analysis Program (http://www.abgent.com/sumoplot.html) was used to predict and
score sumoylation sites within the FOXL2 protein (upper panel). B. Sequence alignment of the FOXL2 region surrounding the putative sumoylation
sites using the ClustalW2 Web based tool (right panel). In grey is highlighted the forkhead domain. In pink the SUMO consensus sequences K25, K87,
K114, K150, with higher score, in blue those with lower scores (K36, K48, K54).
doi:10.1371/journal.pone.0009477.g004
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PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9477Figure 5. Identification and characterization of putative FOXL2 sumoylation sites. A. Mutations of K114, K150 and KFULL results in a
strong reduction of the largest sumoylated band: COS 7 cells were transfected with pCRUZ-myc-FOXL2 wild type or in the mutated forms, with and
without pCRUZ-HA-SUMO-1. 48 h after transfection cells were lysed and 50 ug of protein were analysed by western blotting with anti-myc antibody.
The largest sumoylated band is absent in K114, K150, and K-FULL. B. Mutation of K114 or K150 affects FOXL2 cellular localization: pCRUZ-myc-FOXL2
(WT, K25R, K87R, K114R, K150R, FULL) and pCRUZ- HA-SUMO-1 were co-transfected in COS-7 cells. The intracellular distribution of FOXL2 (red) and
SUMO-1 (green) was detected by indirect immunofluorescence with mouse anti-myc and rabbit anti-HA primary antibodies and Alexa Fluor 633 anti-
mouse and Alexa Fluor 488 anti-rabbit secondary antibodies. Yellow spots show the overlap (co-localization) of the two signals. C., D. Mutation of
putative sumoylation sites results in changes of FOXL2 transcriptional activity: (C) COS-7 cells were co-transfected with pGL3-StAR luciferase reporter
vector and wild-type or mutated FOXL2. Reporter Luciferase activity expressed from the StAR promoter was measured. Luciferase activity is reported
as relative activity. It is the mean of at least 4 independent experiments, normalized to the reporter gene Renilla, encoded by a pTRLK vector, used as
an internal control, and compared to promoter activity alone. Significance was estimated using Student’s t-Test, (*) p,0.01, (**),0.001, (***),0.0001,
(****),10
27 (D) COS-7 cells were co-transfected with pGL3-StAR luciferase reporter vector, and pCRUZ-myc-FOXL2 wild-type or pCRUZ-myc-FOXL2-
KFULL, with or without pCRUZ-HA-SUMO-1. The mutation of all 4 putative sumoylation sites (FOXL2-KFULL) leads to a level of FOXL2 inhibition
independent of the addition of SUMO-1, whereas wild-type mediated inhibition is increased by SUMO-1. Significance was estimated using Student’s
t-Test and reported in the chart.
doi:10.1371/journal.pone.0009477.g005
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which harbours 15 potential forkhead-responsive recognition
motifs, in CHO (Chinese hamster ovarian) cells [17]. To assess
any effects of FOXL2 sumoylation on transcriptional activity, we
carried out a series of transactivation assays with luciferase as a
reporter gene, driven by the 972 bp promoter of the human StAR
gene in the presence or absence of wild type FOXL2 and mutated
forms, each of them alone or along with SUMO-1. Studies were
carried out both in CHO (data not shown) and COS-7 cells.
Confirming earlier findings [17], FOXL2 sharply inhibited StAR
transcription (Fig. 5C). We further showed that sumoylation
increased the extent of repression (Fig. 5D). All single FOXL2
mutants K25R, K87R, K114R and K150R have significantly
decreased activity on the StAR promoter, and the effect is
confirmed with the FOXL2-KFULL mutated form (Fig. 5C).
The reduction in repression activity of K25 and K87, since do not
seem to be sumoylation sites, might be due to a different
mechanism, such as alteration in DNA/protein binding.
All the data collected so far suggest that the increase in the
repressing activity of the FOXL2 in presence of SUMO-1 is likely
due in large part to stabilization of FOXL2, although increased
binding of FOXL2 to DNA might play a role, as suggested for
SOX9 [6]. Additional transactivation assays were carried out co-
transfecting FOXL2 and increasing amounts of PIAS1 and UBC9
in COS-7 cells, to test whether FOXL2 transcriptional activity,
like that of SOX9, is affected by PIAS1 in both SUMO-ligase-
dependent and independent manners [7] (Fig. 6). The responses of
the StAR promoter construct to PIAS1, UBC9 and FOXL2
expression showed that FOXL2 was clearly a repressor of the StAR
promoter, whereas PIAS1 and UBC9 alone effectively stimulated
the StAR promoter in a dose-dependent manner (Fig. 6).
Furthermore, these results imply that the effects of FOXL2 on
the StAR promoter are strongly modulated by interactions with
other transcriptional modulators, in this case PIAS1 and UBC9.
Discussion
As a forkhead transcription factor with a primary role in follicle
and eyelid development, the importance of FOXL2 in ovarian
development and function is unquestioned, but its expression is
under complex transcriptional control [18], and it has not been
known how its action might be modulated during gonadal
development. It is now clear that sumoylation is a vital control
of FOXL2, and it shows an intriguingly symmetrical action in the
yin and yang of FOXL2 and SOX9 in the determination of sex
and gonadal development.
Sumoylation affects many processes (see Introduction), and has
been suggested to be involved in reproductive functions [19,20].
SUMO-1 protein is widely expressed in various tissues, and in
particular it has already been reported in the entire granulosa cell
population of all follicles, from primordial to early antral stage, in
ovaries of immature mice [14]. Stimulation of LH receptors in
granulosa cells results in down-regulation of SUMO-1 expression
with concomitant induction of ovulation [14]. SUMO-1 has also
been localized in male germ cells and somatic cells of mouse and
rat testes [19] as well as in human male germ and somatic cells
[20]. A role of SUMO-1 in modulating steroid action and
potentially diverse functions during spermatogenesis has been
suggested [20], presumably driven by SOX9.
In this study, we report that the modification of FOXL2 by
SUMO-1 in transiently transfected monkey kidney cell lines has
profound effects on its stability and cellular localization, with an
apparent resultant effect on transcriptional activity. We have also
shown comparable sumoylation for endogenous mouse Foxl2
(Fig. 1D, E). It seems very likely that endogenous human FOXL2
is also comparably sumoylated, though that has not been directly
demonstrated.
As for the sites of substitution, FOXL2 sumoylation has been
recently reported [21,22]. Kuo et al [22] indicate K25 as the only
sumoylation site. Here we show that in fact the four predicted
sumoylated sites with the highest score according to SUMOplot
prediction are all likely to be involved in FOXL2 function, because
they affect localization (K114R, K150R, KFULL); sumoylation
(K114R, K150R, KFULL); and transcriptional activity (all the
four mutations singly and all together). In our results, a sumoylated
band is present in K25 and K87 FOXL2 mutants, while it is
almost completely lost in K114R, K150R and KFULL. It may be
that sumoylation can affect different sites with different efficiency
in different cellular environment. Although FOXL2 has 4
sumoylation sites, a mutation in K114 or K150 did not reduce
the molecular weight but only decreased/abrogated the intensity
of the 105–160 KDa band(s). These results suggest that FOXL2 is
more likely modified at a major FOXL2 sumoylation site with a
poly-SUMO-1 chain rather than being mono-sumoylated at 4
different lysines.
Taking into account the comparable effects on both FOXL2
and SOX9, sumoylation may be a critical regulator of a wide
variety of HOX transcription factors. In the gonad in particular,
the parallelism of sumoylation and its effects on FOXL2 and its
mutual antagonist SOX9 in differentiation is striking. As with
SOX9 [6,7], PIAS1 interacts directly with FOXL2 in two-hybrid
assays and co-immunoprecipitation, enhancing sumoylation and at
least partially inhibiting degradation by the proteasome pathway.
The analogy extends to effects on transcriptional activity. In COS-
7 cells, PIAS1 stimulated the SOX9-dependent transcriptional
activity of a Col2a1 promoter-enhancer reporter, and this increase
in reporter activity was followed by an increase in the cellular
Figure 6. PIAS1 and UBC9 in contrast to FOXL2, activate StAR
promoter. COS-7 cells were co-transfected with pGL3-StAR luciferase
reporter vector, and increasing amounts (1.5, 3 mg) of PIAS1 or UBC9,
with or without FOXL2 (1 mg). Relative luciferase activity is compared to
that of promoter activity alone. Luciferase activity is reported as relative
activity, as the mean of at least 4 independent experiments, normalized
to the reporter gene Renilla, encoded by pTRLK vector, used as an
internal control, and compared to promoter activity alone. Statistical
significance was estimated with Student’s t-Test, p-values ,0.05 are
significative, (*) p,0.01, (**) p,0.001.
doi:10.1371/journal.pone.0009477.g006
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promoter activators, and showed an effect opposite to FOXL2,
which acts as a repressor of the StAR promoter.
It is important to note that the effects of sumoylation – especially
because it is balanced to some extent by de-sumoylation – are not
all-or-none, but rather provide a finer modulation of the levels and
localization of the transcription factors. Thus, although SUMO
modulation changes the effective level of FOXL2 or SOX9
activity, there is no evidence that sumoylation might differentially
affect one of the transcription factors; and it therefore remains
unclear if it critically affects the outcome of FOXL2/SOX9
competition in sex determination. As we have discussed elsewhere,
that competition is certainly governed by other factors as well.
They include the over-riding power of the Y chromosome gene
SRY in determining SOX9 expression and testis determination, as
well as the timing of SRY/SOX9 vs. FOXL2 expression [23]. On
the other hand, quantitative changes in the level of their activity
can be consequential and can in fact be determinative, as seen by
the profound effects and partial sex reversal shown in individuals
heterozygous and thereby haploinsufficient for FOXL2 or SOX9.
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